GLP-1 Drugs Work in Rare Genetic Obesity, Study Shows
A new mouse study found all three leading GLP-1 drugs produce weight loss in MC4R gene deficiency — the most common genetic cause of obesity.
May 18, 2026 · 3 min read
A study published in the International Journal of Obesity in April 2026 found that semaglutide, tirzepatide, and retatrutide all produced significant weight loss in mice with MC4R gene deficiency — the most common identifiable single-gene cause of severe obesity. The results suggest GLP-1 agents may be effective treatment options for patients who have historically had few pharmacological options because their obesity is driven by a pathway these drugs were not originally designed to target.
What the Study Found
Researchers administered semaglutide, tirzepatide, or retatrutide to MC4R knockout (KO) mice — animals genetically engineered to lack the melanocortin 4 receptor — for 21 days and measured effects on body weight, body composition, and metabolic markers.
Weight loss outcomes:
| Drug | Mean body weight reduction |
|---|---|
| Semaglutide | 19.7 ± 4.1% |
| Tirzepatide | 31.6 ± 7.6% |
| Retatrutide | 24.1 ± 5.8% |
All three drugs significantly outperformed vehicle control. Beyond weight, all three improved plasma insulin levels, HOMA-IR (a measure of insulin resistance), cholesterol, and markers of liver damage (AST and ALT), and reduced liver hypertrophy — a common complication in MC4R-deficient obesity.
Why MC4R Deficiency Matters
The melanocortin 4 receptor (MC4R) is a central regulator of appetite and energy balance. Mutations that reduce or eliminate MC4R function cause severe, early-onset obesity that is resistant to lifestyle intervention. It's estimated that loss-of-function MC4R variants are present in roughly 1–6% of people with severe obesity, making it the most common genetic form of the disease.
The significance of this study — and of GLP-1 drugs for MC4R-deficient patients more broadly — is that GLP-1 receptor pathways and the POMC-MC4R pathway are distinct in the brain. Earlier mechanistic work suggested GLP-1 drugs would have attenuated effects when MC4R is non-functional. That the three drugs still produced substantial weight loss in MC4R KO mice suggests they recruit other signaling pathways sufficient to drive meaningful effects.
A complementary human study, published in Nature Medicine in August 2025, analyzed SURMOUNT-1 trial participants with pathogenic MC4R mutations (32 of 2,291 participants, or 1.4%). Tirzepatide produced comparable weight loss in carriers vs. non-carriers — 18.3% vs. 19.9% at 72 weeks — providing clinical-grade evidence that tirzepatide is effective even in the most common genetic obesity subtype.
What to Watch
This research is preclinical (mouse models), not a clinical trial. The human SURMOUNT-1 subgroup analysis for tirzepatide is the best current evidence that the mouse findings translate to humans — and for that one drug, the translation appears to hold.
Whether semaglutide and retatrutide show equivalent efficacy in human MC4R-deficient populations is not yet known; the IJO study establishes the biological plausibility but not the clinical confirmation. For the rare patient with confirmed MC4R-deficient obesity, this research adds to the evidence base for considering GLP-1 therapy, but the conversation belongs with an endocrinologist or obesity medicine specialist.
For background on how these drugs work at the receptor level, see how does retatrutide work and the semaglutide complete guide.
Sources
Sources